What patent covers Leukine (sargramostim), and who owns it?
Leukine is the brand name for sargramostim (a recombinant GM‑CSF). Patents covering sargramostim products are held by the drug’s original developer and/or later holders of specific formulation, manufacturing, or use-related IP rights. The exact “Leukine patent” depends on which part you mean: the original biologic molecule, a specific branded manufacturing process, or later changes (for example, a particular indication or formulation). Public patent coverage is fragmented across multiple patent families and jurisdictions, so “the” patent number is usually not a single document.
When do Leukine patents expire (U.S. and internationally)?
Biologics like sargramostim typically have multiple layers of protection, so expiry can happen on different timelines:
- Patent term expiry for specific patents (varies by patent filing/grant dates).
- Regulatory exclusivity periods that can delay market entry for biosimilars beyond the first patent that expires.
- Country-by-country differences in how exclusivity and patent term adjustments work.
To give an exact expiry date, you need either the specific patent (number/publication) or at least the country you care about (for example, U.S. vs EU), plus whether you mean the branded product or biosimilar-related protections.
Are there biosimilars to Leukine, and can they launch before the patents expire?
Sargramostim biosimilar entry depends on the interaction between:
- Patent coverage (what is still enforceable for sargramostim in that jurisdiction), and
- Biosimilar regulatory pathways and exclusivity.
If a biosimilar developer files and then challenges or works around listed patents, that can affect whether entry happens before every individual patent in the family ends. The practical outcome in many biologics programs is that some biosimilars can enter earlier than the “last” patent would suggest, but only if key blocking patents are resolved or expire.
Which kinds of patents usually protect Leukine-like biologics?
For GM‑CSF biologics such as sargramostim, patent estates commonly include:
- Composition-of-matter patents tied to the biologic sequence.
- Manufacturing/process patents (how the biologic is produced).
- Formulation and device-related patents (how the drug is stabilized/delivered).
- Method-of-use patents (specific indications, dosing regimens, or patient populations).
Because your search intent may be “find the blocking patent,” it helps to identify whether you’re looking for molecule protection, a process patent, or an indication/use patent.
How to find the exact “Leukine patent” you mean
A precise answer requires one of the following inputs:
- The jurisdiction (U.S., EP, etc.).
- A patent number or publication (even partial).
- Whether you want the original sargramostim molecule patent, a specific Leukine label indication, or patents relevant to biosimilar entry.
If you share any of those details, I can narrow to the specific patent(s) and give the correct expiration logic.
What information should you check in public records?
For biologic patent searches tied to branded products, you typically verify:
- Patent numbers/publication IDs and assignee/owner.
- Filing dates and grant dates (for term).
- Listed regulatory/approval-linked patents (where available).
- Whether patents are still enforceable, expired, or subject to litigation or terminal disclaimers.
If you meant a “patent challenge” or litigation: what happens next?
In biosimilar competition, disputes often center on which patents block approval or launch. Outcomes can include:
- Patent invalidation or non-infringement decisions.
- Settlement agreements that set delayed launch dates.
- Narrowing of which patents remain at issue.
Those outcomes are highly case-specific, so the exact timeline depends on the relevant patent and jurisdiction.
---
Sources
I don’t have the provided source documents for “Leukine medication patent” in this chat, so I can’t cite specific patent numbers, owners, or expiry dates accurately. If you paste a patent number/publication, a link, or tell me the country (e.g., “U.S. sargramostim Leukine patent”), I’ll answer with exact cited details.